Want to see COYA full AI Analyst Report?
COYA Stock Chart & Stats
$4.78
-$0.10(-1.62%)
At close: 4:00 PM EST
$4.78
-$0.10(-1.62%)
Day’s Range― - ―
52-Week Range$3.71 - $7.75
Previous CloseN/A
Volume16.99K
Average Volume (3M)266.35K
Market Cap
$106.73M
Enterprise Value$38.49
Total Cash (Recent Filing)$50.72M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Aug 18, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding23,457,184
10 Day Avg. Volume216,274
30 Day Avg. Volume266,345
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)2.26
Price to Sales (P/S)12.21
P/FCF Ratio-9.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.25Price Target Upside219.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.34
Revenue Forecast (FY)$2.71M
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressFast Track designation and IND acceptance materially improve regulatory engagement and can shorten development timelines and review priority. These designations raise the long-term probability of advancing COYA 302 through pivotal studies and attracting partner interest for commercialization.
Financing FlexibilityAn open $30M ATM facility gives the company a durable, flexible capital source to support multi-phase clinical programs without requiring single large financings. This ability to access equity over time reduces short-term liquidity stress while supporting ongoing R&D execution.
Low Financial LeverageZero reported debt meaningfully lowers financial risk and interest obligations, preserving cash for R&D and trial execution. With no debt service pressure, management has strategic flexibility to time financings, partnerships, or milestone-driven investments over the medium term.
Bears Say
Ongoing Cash BurnConsistent negative operating and free cash flow indicate continued consumption of cash to fund trials and operations. Over the next several quarters this requires external capital to maintain programs, constraining autonomy and creating execution risk if markets tighten or milestones slip.
Persistent LossesSharp revenue growth has not translated into profitability; gross margins remain low and net losses are large. Sustained negative earnings and negative ROE limit the company's ability to self-fund development and increase reliance on dilutive capital or partnerships until clinical success improves economics.
Revenue Model DependenceBusiness model depends on milestone, collaboration, and licensing receipts rather than recurring product revenue. This creates volatile, milestone-timed income and sustained dependency on partners and capital markets, increasing long-term cash flow uncertainty until product commercialization.
Coya Therapeutics, Inc. News
COYA FAQ
What was Coya Therapeutics, Inc.’s price range in the past 12 months?
Coya Therapeutics, Inc. lowest stock price was $3.71 and its highest was $7.75 in the past 12 months.
What is Coya Therapeutics, Inc.’s market cap?
Coya Therapeutics, Inc.’s market cap is $106.73M.
When is Coya Therapeutics, Inc.’s upcoming earnings report date?
Coya Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 25 days.
How were Coya Therapeutics, Inc.’s earnings last quarter?
Coya Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.416 by $0.096.
Is Coya Therapeutics, Inc. overvalued?
According to Wall Street analysts Coya Therapeutics, Inc.’s price is currently Undervalued.
Does Coya Therapeutics, Inc. pay dividends?
Coya Therapeutics, Inc. does not currently pay dividends.
What is Coya Therapeutics, Inc.’s EPS estimate?
Coya Therapeutics, Inc.’s EPS estimate is -0.35.
How many shares outstanding does Coya Therapeutics, Inc. have?
Coya Therapeutics, Inc. has 23,457,184 shares outstanding.
What happened to Coya Therapeutics, Inc.’s price movement after its last earnings report?
Coya Therapeutics, Inc. reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.416. Following the earnings report the stock price went up 2.632%.
Which hedge fund is a major shareholder of Coya Therapeutics, Inc.?
Currently, no hedge funds are holding shares in COYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Coya Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.25 (219.04% Upside)
$15.25 (219.04% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
38.71%
Trailing 12-Months
Company Description
Coya Therapeutics, Inc.
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
COYA Stock 12 Month Forecast
Average Price Target
$15.25
▲(219.04% Upside)
Technical Analysis
Ownership Overview
4.42% Insiders
4.45% Mutual Funds
0.01% Other Institutional Investors
86.94% Public Companies and
Individual Investors